Atossa Therapeutics announces recognition of Breast Cancer Awarenss Month

Atossa Therapeutics announced its recognition and support of Breast Cancer Awareness Month this October; highlighting the importance of increasing awareness, advancing research, and driving progress toward innovative treatments for breast cancer. Approximately one in eight women will be diagnosed with breast cancer in their lifetime, so this annual campaign serves as a powerful reminder of the ongoing need for education, early detection, prevention, and access to effective treatment options. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. This year’s Breast Cancer Awareness Month takes on added significance with the recent implementation of the U.S. Food and Drug Administration’s updated rule under the Mammography Quality Standards Act. The new rule, which became effective on September 10, 2024, requires healthcare providers to notify women of their breast density results following a mammogram. Dense breast tissue is a known risk factor for breast cancer, and women with this condition are encouraged to consult with their healthcare providers about additional screening options to ensure earlier detection.